title: The dual neuroprotective-neurotoxic profile of cannabinoid drugs.
abstract: Extensive in vitro and in vivo studies have shown that cannabinoid drugs have neuroprotective properties and suggested that the endocannabinoid system may be involved in endogenous neuroprotective mechanisms. On the other hand, neurotoxic effects of cannabinoids in vitro and in vivo were also described. Several possible explanations for these dual, opposite effects of cannabinoids on cellular fate were suggested, and it is conceivable that various factors may determine the final outcome of the cannabinoid effect in vivo. In the current review, we focus on one of the possible reasons for the dual neuroprotective/neurotoxic effects of cannabinoids in vivo, namely, the opposite effects of low versus high doses of cannabinoids. While many studies reported neuroprotective effects of the conventional doses of cannabinoids in various experimental models for acute brain injuries, we have shown that a single administration of an extremely low dose of Δ(9) -tetrahydrocannabinol (THC) (3-4 orders of magnitude lower than the conventional doses) to mice induced long-lasting mild cognitive deficits that affected various aspects of memory and learning. These findings led to the idea that this low dose of THC, which induces minor damage to the brain, may activate preconditioning and/or postconditioning mechanisms and thus will protect the brain from more severe insults. Indeed, our recent findings support this assumption and show that a pre- or a postconditioning treatment with extremely low doses of THC, several days before or after brain injury, provides effective long-term cognitive neuroprotection. The future therapeutical potential of these findings is discussed.
authors.affiliation: The Adelson Center for the Biology of Addictive Diseases and The Mauerberger Chair in Neuropharmacology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. sarney@post.tau.ac.il
authors.forename: Yosef
authors.initials: Y
authors.lastname: Sarne
authors.forename: Fadi
authors.initials: F
authors.lastname: Asaf
authors.forename: Miriam
authors.initials: M
authors.lastname: Fishbein
authors.forename: Mikhal
authors.initials: M
authors.lastname: Gafni
authors.forename: Ora
authors.initials: O
authors.lastname: Keren
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects*; D002186:Cannabinoids / Q000009:adverse effects / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000494:pharmacology*; D020258:Neurotoxicity Syndromes / Q000209:etiology
chemical_list: D002186:Cannabinoids; D018696:Neuroprotective Agents